New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Unicycive Therapeutics, Inc.

Contributing Author

Recent Articles by Unicycive Therapeutics, Inc.

Aug-26	Unicycive Therapeutics to Participate in Upcoming Investor Events in September UNCY GlobeNewswire
Aug-18	Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease UNCY GlobeNewswire
Aug-14	Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update UNCY GlobeNewswire
Jul-24	Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology UNCY GlobeNewswire
Jul-08	Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement UNCY GlobeNewswire
Jul-07	Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference UNCY GlobeNewswire
Jun-30	Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis UNCY GlobeNewswire
Jun-17	Unicycive Therapeutics, Inc. Announces Reverse Stock Split UNCY GlobeNewswire
Jun-10	Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis UNCY GlobeNewswire
May-22	Unicycive Therapeutics to Present at Upcoming Investor Conferences UNCY GlobeNewswire
May-21	Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders UNCY GlobeNewswire
May-14	Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update UNCY GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.